Preparation method and application of MnO2 coated lipid nanoparticles
By generating MnO2 coated lipid nanoparticles on the surface of MnO2 nanoparticles, the charge flip is achieved by reacting CaO2 inside the liposome with external MnCl2, which solves the problem that MnO2 nanodrugs are difficult to be uptaken by cancer cells in normal tissues, and improves the Drug uptake efficiency and anti-tumor effects in tumor environment.
Patent Information
- Application Number
- CN202411160088.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-26
AI Technical Summary
Because MnO2 nanodrugs are negatively charged, they are difficult to be ingested by cancer cells, resulting in low toxicity in normal tissues but low uptake efficiency in tumor sites, making it difficult to achieve effective anti-tumor treatment.
Design a MnO2-coated lipid nanoparticles, and react with CaO2 inside the liposome and external MnCl2 to generate MnO2 in situ on the surface of the nanoparticles. CaO2 inside the liposome reacts with external MnCl2 to react on the surface of the liposome MnO2 is generated to achieve charge flip, thereby degrading and exposing positively charged drug-loaded liposomes in the tumor environment, increasing the uptake of cancer cells.
Reduce the uptake of nanodrugs in the systemic circulation and reduce toxicity; in a tumor rich H+/H2O2 environment, MnO2 reacts with H+/H2O2 to degrade, exposing positively charged drug liposomes, and improving the uptake rate of cancer cells to nanodrugs , enhance anti-tumor effect.
Smart Images

Figure CN119015433A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a preparation method and application of MnO2 coated lipid nanoparticles. Background Art
[0002] At present, drug research laboratories have developed a large number of nanomedicines based on manganese dioxide (MnO2). Through various cancer cells and tumor-bearing animals (mainly mice) models, researchers have verified that these MnO2-based nanomedicines have certain application value in various aspects such as tumor drug delivery, chemotherapy sensitization and multi-therapy combined anti-tumor, and can improve the safety and effectiveness of anti-tumor drugs to a certain extent.
[0003] In order to prepare MnO2 nanomedicine, the most commonly used method is potassium permanganate (KMnO4) oxidation method, that is, using KMnO4 to oxidize reducing substances such as silicon dioxide (SiO2) nanoparticles, albumin, ethanol, etc. For example, the literature (Yang, Guangbao, et al. "Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses." Nature communications 8.1 (2017): 902.) uses KMnO4 to react with silicon dioxide nanoparticles to form a MnO2 coating layer on the surface of silicon dioxide, and then etches the middle SiO2 to form hollow MnO2 nanoparticles.
[0004] Studies have shown that due to the negative charge on the cell membrane surface, negatively charged nanoparticles are less likely to be taken up by cells than positively charged particles. MnO2 has a negative charge, and when it is delivered to the tumor site as a carrier, it may face the problem of being difficult to be taken up by cancer cells, but this negative charge can ensure that it is not taken up in normal tissues. Therefore, it is urgent to develop an intelligent charge-reversible MnO2 drug carrier that can significantly reduce toxic side effects and ensure a high uptake rate of cancer cells. Summary of the invention
[0005] In view of the shortcomings of the prior art, the present invention provides a method for preparing MnO2-coated lipid nanoparticles and applications thereof, and utilizes positively charged liposomes and negatively charged degradable MnO2 coatings to design and prepare charge-reversal drug carriers, which can achieve MnO2 coating on the surface of nanoparticles, and utilizes the reaction of CaO2 inside the liposomes with external MnCl2 to generate MnO2 in situ on the surface of the liposomes.
[0006] To achieve the above objectives, the technical solution of the present invention is implemented through the following technical solutions:
[0007] A method for preparing MnO2-coated lipid nanoparticles, the preparation method comprising the following steps:
[0008] S1, NH3·H2O and anionic phospholipids were mixed in a volume mass ratio of 400-600 μL: 20-40 mg, and then added to the oil phase, and stirred evenly to obtain microemulsion 1 for use;
[0009] S2, mixing H2O2, 4M CaCl2 solution and oil phase in a volume ratio of 0.8-1.2:0.8-1.2:35-45, stirring evenly, to obtain microemulsion 2;
[0010] S3, mixing microemulsion 1 and microemulsion 2, stirring at room temperature for 30 min, then adding ethanol to break the emulsion, centrifuging and collecting the precipitate;
[0011] S4, washing the precipitate with anhydrous ethanol, and then dissolving the precipitate in chloroform to obtain a CaO2 / DDP@phospholipid chloroform solution;
[0012] S5. Add DOPC, cholesterol and DSPE-PEG chloroform solution to the CaO2 / DDP@phospholipid chloroform solution prepared above, mix thoroughly, spin-dry the chloroform, add an excess of 10 mg / mL MnCl2 solution, disperse by ultrasound for 20 seconds, and then dry to obtain MnO2@Lipo nanoparticles. During the preparation process of the entire system, the molar ratio of CaCl2, DOPC, cholesterol, DSPE-PEG and manganese chloride is 10:1.2:1.2:0.3:10.
[0013] Preferably, the anionic phospholipid is any one of phosphatidylserine, dioleoylphosphatidic acid sodium salt, phosphatidylinositol, phosphatidic acid and cardiolipin substances.
[0014] Preferably, the oil phase is prepared by mixing cyclohexane and Igepal CO-520 in a volume ratio of 50-80:20-40.
[0015] Preferably, in step S1, the volume ratio of the oil phase to NH3·H2O is 50:2-3.
[0016] Preferably, the molar concentration of the CaCl2 solution in step S2 is 3-5M.
[0017] Preferably, in step S3, the volume ratio of microemulsion 1 and microemulsion 2 is 1:1.
[0018] Preferably, the centrifugation in step S3 is performed at a rotation speed of 12000 rpm for 15 min.
[0019] The MnO2-coated lipid nanoparticles prepared above are used for delivery or co-delivery of chemotherapeutic drugs, antibodies, and molecular targeted drugs, and the specific application method is to load the drug during the preparation stage of the MnO2-coated lipid drug-loaded nanoparticles, and the specific loading method includes the following two methods:
[0020] (1) For water-soluble drugs: dissolve the water-soluble drugs in the microemulsion 2 of step S2, then mix the microemulsion 2 containing the dissolved drugs with the microemulsion 1, and then prepare the nanoparticles according to the normal steps;
[0021] (2) For fat-soluble drugs: dissolve the fat-soluble drugs in chloroform, add them to the CaO2 / DDP@phospholipid chloroform solution in step S5, mix them with DOPC, cholesterol and DSPE-PEG chloroform solutions, and then prepare nanoparticles according to normal steps.
[0022] The present invention provides a preparation method and application of MnO2-coated lipid nanoparticles, which have the following advantages over the prior art:
[0023] The nanomedicine prepared by the preparation method has the charge reversal ability of tumor tissue response: in the systemic circulation, due to the presence of MnO2 coating, the nanomedicine has a negative charge as a whole, so that it is less absorbed in normal tissues and has reduced toxicity; + / H2O2 environment, the outer layer of MnO2 and H + / H2O2 undergoes chemical reactions and degrades and falls off, exposing positively charged drug-loaded liposomes, increasing the uptake of nanomedicines by cancer cells and enhancing the anti-tumor effect; and the uses of the carrier include but are not limited to the delivery or co-delivery of tumor therapeutic molecules such as chemotherapeutics, antibodies, and molecular targeted drugs. For drugs of different properties, the optional drug loading methods are different. Water-soluble drugs can be dissolved in the aqueous phase of the microemulsion, and they are eventually loaded into the hydrophilic cavity of the liposome; while fat-soluble drugs can be added with chloroform solution during the film-forming process, and are eventually loaded into the phospholipid bilayer. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is the FTEM electron microscope image of MnO2@LipoDOX of the present invention;
[0025] Figure 2 This is the element mapping diagram of MnO2@LipoDOX under the electron microscope field of view of the present invention;
[0026] Figure 3 Schematic diagram of the storage stability of MnO2@LipoDOX of the present invention;
[0027] Figure 4 Schematic diagram of the potential of MnO2@LipoDOX of the present invention in ultrapure water (left) and sodium acetate solution (right);
[0028] Figure 5 Schematic diagram of the potential change of MnO2@LipoDOX of the present invention in a simulated tumor microenvironment (pH 6.5+100 μM H2O2) and a normal environmental buffer (pH 7.4);
[0029] Figure 6 Schematic diagram of the detection of H+ / H2O2-sensitive drug release properties of MnO2@LipoDOX of the present invention;
[0030] Figure 7 This is a schematic diagram of the cytotoxicity of MnO2@LipoDOX of the present invention to MDA-MB-231 cells. DETAILED DESCRIPTION
[0031] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention is clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Embodiment 1:
[0033] Preparation of unloaded MnO2-coated lipid nanoparticles:
[0034] 500 μL NH3·H2O and 30 mg DOPA were added to 10 mL of the oil phase (cyclohexane: Igepal CO-520 volume ratio of 71:29) and stirred for 10 min, which was recorded as microemulsion 1;
[0035] 250 μL H2O2 and 250 μL CaCl2 solution (4 M) were added to 10 mL of oil phase (cyclohexane: Igepal CO-520 volume ratio of 71:29), stirred for 10 min and recorded as microemulsion 2;
[0036] Microemulsions 1 and 2 were mixed and stirred at room temperature for 30 min, then 15 mL of ethanol was added to break the emulsion, centrifuged at 12000 rpm for 15 min, and the precipitate was collected;
[0037] The precipitate was washed three times with 10 mL of anhydrous ethanol and finally dissolved in 15 mL of chloroform to obtain CaO2@DOPA nanoparticles;
[0038] To the CaO2 / DDP@DOPA chloroform solution prepared above, add 3 mL of DOPC (40 mM), 3 mL of cholesterol (40 mM) and 3 mL of DSPE-PEG (10 mM) chloroform solution, mix thoroughly, spin dry the chloroform, add 3 mL of 10 mg / mL manganese chloride solution, disperse by ultrasonication for 20 s, and then dry to obtain MnO2@Lipo nanoparticles.
[0039] Embodiment 2:
[0040] Preparation of drug-loaded MnO2@Lipo nanoparticles: Taking water-soluble doxorubicin hydrochloride (DOX·HCl) as an example:
[0041] 500 μL NH3·H2O and 30 mg DOPA were added to 10 mL of the oil phase (cyclohexane: Igepal CO-520 volume ratio of 71:29) and stirred for 10 min, which was recorded as microemulsion 1;
[0042] 250 μL H2O2 and 250 μL CaCl2 solution (4 M) were added to 10 mL oil phase (cyclohexane: Igepal CO-520 volume ratio was 71:29), stirred for 10 min and recorded as microemulsion 2. 5 mg doxorubicin hydrochloride was added to microemulsion 2 and mixed evenly to obtain mixed microemulsion 2.
[0043] Microemulsion 1 and mixed microemulsion 2 were mixed, stirred at room temperature for 30 min, and then 15 mL of ethanol was added to break the emulsion, centrifuged at 12000 rpm for 15 min, and the precipitate was collected;
[0044] The precipitate was washed three times with 10 mL of anhydrous ethanol and finally dissolved in 15 mL of chloroform to obtain DOX@CaO2@DOPA nanoparticles;
[0045] To the DOX@CaO2 / DDP@DOPA chloroform solution prepared above, add 3 mL of DOPC (40 mM), 3 mL of cholesterol (40 mM) and 3 mL of DSPE-PEG (10 mM) chloroform solution, mix thoroughly, spin dry the chloroform, add 3 mL of 10 mg / mL manganese chloride solution, disperse by ultrasonication for 20 s, and then dry to obtain MnO2@LipoDOX nanoparticles.
[0046] Detection:
[0047] 1. The MnO2@LipoDOX nanoparticles prepared in Example 2 were diluted to a concentration of 0.5 mg / mL, dispersed evenly by ultrasonication, and 20 μL was accurately dropped on the carbon film copper mesh. After the solvent was evaporated, the morphology of the nanoparticles was observed using a field emission transmission electron microscope (FTEM, 200 kV), and mapping element analysis was performed. The specific results are as follows: Figure 1 and Figure 2 shown.
[0048] 2. Stability test: The MnO2@LipoDOX nanoparticles prepared in Example 2 were dispersed in saline and ultrapure water at a concentration of 1 mg / mL, and then ultrasonically dispersed to make them uniformly dispersed. Then, they were sealed and stored in a refrigerator at 4°C. The hydrated particle size of MnO2@LipoDOX in the two media was measured every day by a dynamic light scattering instrument. The specific results are as follows: Figure 3 shown.
[0049] 3. DOX-loaded cationic liposomes (denoted as LipoDOX, with the same phospholipid composition as MnO2@LipoDOX) were prepared by conventional thin film dispersion hydration method. LipoDOX, MnO2@LipoDOX and unloaded MnO2@Lipo (prepared in Example 1) were dispersed in two media (ultrapure water and sodium acetate solution) at a concentration of 0.5 mg / mL, respectively. The zata potential of the nanoparticle surface was detected by dynamic light scattering. The specific results are shown in Figure 4 As shown, the left side is ultrapure water and the right side is sodium acetate solution.
[0050] 4. MnO2@LipoDOX was dispersed in two media at a concentration of 0.5 mg / mL: PBS buffer at pH 7.4 and PBS buffer at pH 6.5 containing 100 μM H2O2 (simulating tumor microenvironment), both at 37°C. The potential of the nanoparticles was detected and recorded at the preset time points. The specific results are shown in Figure 5 shown.
[0051] 5. Seal the nanoparticle solution containing 10 mg MnO2@LipoDOX in a dialysis bag with a molecular weight cutoff of 2000Da, then immerse the dialysis bag in three media (① PBS buffer at pH 7.4, ② PBS buffer at pH 6.5, ③ PBS buffer at pH 6.5 and containing 100μM H2O2), and draw 2mL of PBS external solution at set time intervals (0.5, 1, 2, 4, 8, 12, 24, 48h), and detect the cisplatin concentration therein by high performance liquid chromatography. At the same time, add 2mL of fresh buffer with the same composition as the original buffer after each sampling. The specific test results are as follows: Figure 6 shown.
[0052] 6. First, free DOX, ordinary DOX liposomes (LipoDOX), MnO2@LipoDOX, and MnO2@Lipo were dispersed in DMEM culture medium to prepare a certain concentration of drug solution. Then, MDA-MB-231 cells in the logarithmic growth phase were inoculated into 60 wells inside a 96-well plate at a density of 5×104 / well / 0.1mL, and 200μL of normal saline was added to the remaining peripheral wells and cultured in an incubator overnight. After the cells were completely attached to the wall, the original culture medium was discarded, and the drug solution diluted to a certain concentration was added and incubated in an incubator for 24h. After that, the culture medium was removed, 20μL of MTT solution (5mg / mL) was added to each well, and after incubation at 37°C for another 4h, the solution was discarded, 150μL of DMSO was added to each well, and the absorbance at a wavelength of 590nm was measured with an enzyme reader after 10min. For specific results, see Figure 7 shown.
[0053] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for preparing MnO2-coated lipid nanoparticles, characterized in that: The preparation method comprises the following steps: S1, NH3·H2O and anionic phospholipids were mixed in a volume mass ratio of 400-600 μL: 20-40 mg, and then added to the oil phase, and stirred evenly to obtain microemulsion 1 for use; S2, mixing H2O2, 4M CaCl2 solution and oil phase in a volume ratio of 0.8-1.2:0.8-1.2:35-45, stirring evenly, to obtain microemulsion 2; S3, mixing microemulsion 1 and microemulsion 2, stirring at room temperature for 30 min, then adding ethanol to break the emulsion, centrifuging and collecting the precipitate; S4, washing the precipitate with anhydrous ethanol, and then dissolving the precipitate in chloroform to obtain a CaO2 / DDP@phospholipid chloroform solution; S5. Add DOPC, cholesterol and DSPE-PEG chloroform solution to the CaO2 / DDP@phospholipid chloroform solution prepared above, mix thoroughly, spin-dry the chloroform, add an excess of 10 mg / mL MnCl2 solution, disperse by ultrasound for 20 seconds, and then dry to obtain MnO2@Lipo nanoparticles. During the preparation process of the entire system, the molar ratio of CaCl2, DOPC, cholesterol, DSPE-PEG and manganese chloride is 10:1.2:1.2:0.3:
10.
2. The method for preparing MnO2-coated lipid nanoparticles according to claim 1, characterized in that: The anionic phospholipid is any one of phosphatidylserine, dioleoylphosphatidic acid sodium salt, phosphatidylinositol, phosphatidic acid and cardiolipin substances.
3. The method for preparing MnO2-coated lipid nanoparticles according to claim 1, characterized in that: The oil phase is prepared by mixing cyclohexane and Igepal CO-520 in a volume ratio of 50-80:20-40.
4. The method for preparing MnO2-coated lipid nanoparticles according to claim 1, characterized in that: In step S1, the volume ratio of the oil phase to NH3·H2O is 50:2-3.
5. The method for preparing MnO2-coated lipid nanoparticles according to claim 1, characterized in that: The volume molar concentration of the CaCl2 solution in step S2 is 3-5M.
6. The method for preparing MnO2-coated lipid nanoparticles according to claim 1, characterized in that: In step S3, the volume ratio of microemulsion 1 and microemulsion 2 is 1:
1.
7. The method for preparing MnO2-coated lipid nanoparticles according to claim 1, characterized in that: The centrifugation in step S3 is carried out at a rotation speed of 12000 rpm for 15 minutes.
8. Use of MnO2-coated lipid nanoparticles prepared by the preparation method according to any one of claims 1 to 7 in the delivery or co-delivery of chemotherapeutic drugs, antibodies, and molecular targeted drugs.
9. The use according to claim 8, characterized in that: The specific application method is to load the drug during the preparation stage of MnO2-coated lipid drug-loaded nanoparticles, and the specific loading method includes the following two methods: (1) For water-soluble drugs: dissolve the water-soluble drugs in the microemulsion 2 of step S2, then mix the microemulsion 2 containing the dissolved drugs with the microemulsion 1, and then prepare the nanoparticles according to the normal steps; (2) For fat-soluble drugs: dissolve the fat-soluble drugs in chloroform, add them to the CaO2 / DDP@phospholipid chloroform solution in step S5, mix them with DOPC, cholesterol and DSPE-PEG chloroform solutions, and then prepare nanoparticles according to normal steps.
